3.5/5
Moderate
evidence
Metabolic health evidence brief
Myo-inositol
Myo-inositol may improve some metabolic and reproductive markers in PCOS, but it is not a general fat-loss or hormone-balancing supplement.
Headline Finding
2023 PCOS guideline review: inositol could be considered by preference, with limited harm and possible metabolic improvements but limited clinical benefits.
Dose Context
PCOS trials often use gram-level daily dosing, sometimes combined with D-chiro-inositol; exact form and ratio remain unresolved.
Important Caveat
Use should follow a PCOS diagnosis and broader care plan. Evidence is not strong enough to promise weight loss, fertility, or cosmetic outcomes.
Source Drawer
Linked Research
- Review 2023 PCOS guideline review
- Meta-analysis PCOS RCT meta-analysis
- Meta-analysis Myo-inositol PCOS meta-analysis
- Review Cochrane PCOS subfertility review
- Review Nutritional supplements PCOS NMA
- Review Insulin-sensitizer NMA
How To Read This Rating
The score reflects evidence that the supplement does its stated job. Some jobs are direct, such as strength, endurance, or recovery; others are indirect, such as sleep, mood, appetite, or health support. A real effect can still receive a cautious practical rating when dose, safety, product quality, or audience fit remain uncertain.
Spot An Evidence Issue?
Send the disputed claim, source link, and why it changes the practical verdict. Corrections that materially affect the claim, dose, caveat, or rating are prioritized.
Report a source or rating issue